Endocrine Oncology Fellowship Programs | Advanced Training Directory

What Is an Endocrine Oncology Fellowship?

Endocrine oncology sits at the intersection of two established subspecialties: endocrinology, diabetes, and metabolism, and hematology-oncology. The clinical focus is the diagnosis and management of malignancies arising from endocrine organs — thyroid, adrenal, parathyroid, pituitary, pancreatic islets, and diffuse neuroendocrine tissue — along with the endocrine consequences of cancer treatment, including immune checkpoint inhibitor–induced endocrinopathies.

This is not a carved-out specialty with its own accreditation pipeline. There is no ACGME-accredited "endocrine oncology fellowship" as a standalone program class. What exists instead is a heterogeneous landscape of advanced training positions at high-volume academic centers, structured as either institutional post-fellowship appointments or as defined tracks within existing accredited programs. Understanding that distinction before you apply is the most important orientation this page can give you.

The field has genuine clinical mass. Differentiated thyroid cancer is the most common endocrine malignancy and its management has grown complex enough to support dedicated subspecialty careers. Neuroendocrine tumors (NETs) are increasing in recorded incidence and now encompass a therapeutically rich landscape of somatostatin analogues, targeted agents, peptide receptor radionuclide therapy (PRRT), and clinical trials. Adrenocortical carcinoma, pituitary carcinoma, and parathyroid carcinoma are rare but require expert-center management. The immune checkpoint inhibitor era has created an entirely new subspecialty niche — endocrine toxicity management — that cuts across all oncology practices. The work is real and the need for trained people is real.

Accreditation Status — Plainly Stated

As of 2025, no standalone ACGME accreditation exists for endocrine oncology fellowship. No separate ABMS board certification pathway exists. This is not a temporary gap that is about to close; the subspecialty has not moved through the formal accreditation petition process at the specialty board level.

What this means practically:

• Positions at academic centers are typically appointed as post-fellowship clinical or research fellowships under institutional graduate medical education or research training office frameworks. They carry institutional credentials, not ACGME program numbers.
• Some fellows train under the umbrella of an ACGME-accredited endocrinology program that has structured an endocrine oncology track in its final year or as a post-fellowship extension. In this case, the ACGME accreditation applies to the parent endocrinology program, not to the oncology track itself.
• Some positions are structured through medical oncology programs at NCI-designated cancer centers, with endocrine tumor focus built into the rotation schedule. Again, the accreditation is the parent hematology-oncology program's.
• Society-recognized training exists in the NET space: the North American Neuroendocrine Tumor Society (NANETS) and the European Neuroendocrine Tumor Society (ENETS) both support educational frameworks and some centers reference these standards in designing their programs. ENETS has a more formalized center-of-excellence designation process. Neither constitutes ACGME or ABMS recognition in the US credentialing sense.
• The American Association of Endocrine Surgeons (AAES) is relevant to the surgical side but not to the medical endocrine oncology training pipeline.

Why this matters to you: when you credential at a future employer, you will document your endocrine oncology training through your CV, program director letter, and institutional appointment documentation — not through a board certificate or ACGME program number. Programs at research-intensive centers with established faculty and documented case volume will credential more legibly than informal positions. Vet that distinction before accepting a position.

Core Clinical Competencies Developed

A well-structured endocrine oncology fellowship builds competency across the following domains. Not every program covers all of them with equal depth; use this list as an evaluation framework when comparing positions.

• Thyroid malignancies: differentiated thyroid cancer (papillary, follicular, Hürthle cell), radioactive iodine selection and dosimetry, TSH suppression strategy, BRAF/RET/RAS-directed therapy, anaplastic thyroid cancer multidisciplinary management, medullary thyroid cancer including hereditary RET mutation surveillance and kinase inhibitor use
• Adrenal malignancies: adrenocortical carcinoma staging, mitotane management, EDP-M chemotherapy protocols, adrenal metastatic disease evaluation, adrenocortical carcinoma genomics
• Neuroendocrine tumors: gastroenteropancreatic and thoracic NETs, functional vs. nonfunctional tumor management, somatostatin receptor imaging interpretation, PRRT candidacy assessment, everolimus and sunitinib protocols, carcinoid syndrome management
• Pituitary neoplasms: aggressive pituitary adenoma and pituitary carcinoma management, temozolomide use, coordination with neurosurgery and radiation oncology
• Parathyroid carcinoma: hypercalcemia management, denosumab and cinacalcet use, surgical planning coordination
• Multiple endocrine neoplasia (MEN) syndromes: MEN1, MEN2A, MEN2B, and MEN4 — germline counseling, surveillance protocol design, cascade testing coordination
• Endocrine toxicities of cancer immunotherapy: checkpoint inhibitor–induced hypophysitis, thyroiditis, adrenal insufficiency, type 1 diabetes, and hypoparathyroidism — diagnosis, grading, steroid protocols, and oncology co-management
• Multidisciplinary tumor board participation: presenting cases, integrating imaging and pathology, coordinating with surgical oncology, nuclear medicine, interventional radiology, and radiation oncology
• Clinical trials: protocol eligibility assessment, informed consent, and management of trial-enrolled patients

Typical Program Structure and Duration

Most endocrine oncology advanced fellowship positions run one to two years. One-year structures are more common and tend to be clinically weighted. Two-year positions usually incorporate a protected research year, often funded through a T32 or institutional training grant.

A representative rotation structure across a one-year program might include:

• Endocrine oncology outpatient clinic (longitudinal, throughout the year)
• Inpatient endocrine oncology or medical oncology consult service
• Multidisciplinary endocrine tumor board (weekly, throughout)
• Nuclear medicine — thyroid and NET imaging, PRRT protocol observation
• Surgical oncology — endocrine surgery operative exposure and surgical planning conferences
• Molecular pathology — endocrine tumor pathology review, genomic report interpretation
• Radiation oncology — treatment planning conferences for thyroid, pituitary, and adrenal cases
• Dedicated research time — variable; ranges from negligible in purely clinical positions to the majority of protected time in research-track positions

Programs at NCI-designated comprehensive cancer centers tend to have the highest case volume and the most structured multidisciplinary exposure. Programs embedded in academic endocrinology divisions outside dedicated cancer centers may offer strong thyroid cancer volume with less breadth in rare tumor types. Neither model is inherently superior; match the structure to your career intent.

Prerequisites and Eligibility Requirements

Requirements vary by institution but the following represent the consistent baseline across the programs in this field:

• Completion of an ACGME-accredited fellowship in endocrinology, diabetes, and metabolism or hematology-oncology prior to the start date. Most programs require this to be complete, not merely in progress, at the time of appointment.
• Medical licensure in the state where the program is located, or eligibility to obtain it within the institutional credentialing window.
• USMLE or COMLEX passage (all Steps or Levels) — institutional credentialing requires this regardless of citizenship or training background.
• ABIM board eligibility or certification in the parent specialty (endocrinology or medical oncology) is typically expected, though some programs will accept fellows who are board-eligible at start and certified by end of year.
• Research productivity: most research-track positions at high-volume centers expect at least one peer-reviewed first-author publication prior to application. Clinical-track positions are more variable.
• IMG-specific requirements: ECFMG certification is required for J-1 or H-1B visa sponsorship. Not all programs sponsor visas for post-fellowship positions; confirm this explicitly during the recruitment process. Verify current requirements directly with ECFMG/Intealth and official sources for your application year.

How to Find and Evaluate Programs

Where to Look

• NCI-designated cancer center websites: Comprehensive cancer centers with endocrine tumor programs are the most reliable place to find structured positions. The NCI maintains the public list of designated centers; work through that list and check the endocrinology or endocrine oncology section of each center's faculty and training pages.
• ENDO annual meeting: The Endocrine Society's annual meeting job board and fellowship fair carry listings for advanced training positions. Attending in person or searching the meeting's career resources is a practical approach.
• NANETS membership and annual symposium: The North American Neuroendocrine Tumor Society annual symposium is where the NET training community concentrates. Networking there connects you to program directors who rarely post positions on general job boards.
• AACE and TES: The American Association of Clinical Endocrinology and the Thyroid Eye Society (for thyroid-adjacent work) have career resources that occasionally surface positions.
• Direct faculty contact: Given the small scale of this field, cold email to productive faculty whose work you know is a legitimate and often effective strategy. A focused, non-generic message referencing specific publications carries weight here.

How to Evaluate a Program

Because no standardized accreditation framework exists, you are doing your own quality assessment. The following criteria matter:

• Case volume: How many new thyroid cancer cases, NET cases, and adrenal malignancy cases does the center manage per year? This information is sometimes published in cancer center annual reports or in NAPBC/NCCN accreditation documents. If it is not public, ask directly.
• Faculty publication record: Search PubMed for the program director and attending faculty. Active research programs produce fellows who can compete for academic positions. Absence of recent publications is informative.
• Prior fellow outcomes: Where did the last two or three fellows go? Academic faculty positions, NCI careers, and pharma medical affairs are the typical tracks. Programs that cannot name their recent fellow outcomes are not tracking their own mission.
• Mentorship structure: Is there a formal mentorship plan with named faculty? Is there a fellow advisory committee? Or is this a service-heavy position with nominal research protected time?
• Funding source: Institutional salary, T32, K12, or departmental funds all have different implications for your autonomy, research agenda, and transition to independence. Understand the funding mechanism before you sign.
• PRRT availability: Peptide receptor radionuclide therapy is a core NET competency. If a center does not offer PRRT clinically, your NET training will be incomplete for contemporary practice.

Application Process and Timeline

There is no centralized match for endocrine oncology fellowships. There is no ERAS portal for these positions. Applications are submitted directly to programs, and the process is entirely decentralized.

Typical Application Components

• Cover letter: Specific to each program. Describe your clinical training background, the research question or clinical problem you want to work on, and why this particular program's work aligns with that. Generic cover letters are obvious and ineffective in a small field where program directors often know your letter writers personally.
• Curriculum vitae: Full academic CV including education, training, publications, presentations, grants, and teaching. Format to academic medicine standards, not a résumé.
• Research statement: Expected for any position with protected research time. One to two pages describing your prior research, the question you plan to pursue, and your longer-term academic trajectory. This is evaluated seriously.
• Three letters of recommendation: At least one should come from your fellowship program director. At least one should speak to research capacity and output. Letters from recognized names in endocrine oncology or neuroendocrine tumor medicine carry weight in a small community.
• Representative publications: Include reprints or preprints of your most relevant work.

Timing

Application cycles vary substantially by program. Some programs post and fill positions on a rolling basis, sometimes more than a year before the start date. Others recruit on a more compressed annual cycle. There is no standardized notification timeline. The practical implication: begin identifying target programs and making contact during the second year of your parent fellowship, not in the final months. See the current season timeline on the PGY Zero data pages for general academic medicine recruiting context.

Interview formats range from a single day of in-person meetings with faculty and current fellows to informal video calls followed by an on-site visit. A site visit before accepting a position is worth the cost.

Research and Scholarly Requirements

Research expectations vary significantly between programs, and this is one of the most important axes of program differentiation.

At NCI-designated comprehensive cancer centers and NIH-adjacent programs, the expectation is that you will produce original scholarship during your training — minimally, one submitted manuscript before completion, and ideally a project that can serve as the basis for a K08 or K23 application. Protected time is a prerequisite for this, and the quality of mentorship in grant development is a differentiating factor worth probing explicitly in interviews.

Translational research opportunities in this field are genuinely rich. Endocrine tumor biology — particularly in NETs, adrenocortical carcinoma, and medullary thyroid cancer — is an active area of molecular investigation. Clinical trials through NCI cooperative groups (ECOG-ACRIN, Alliance, SWOG) and industry-sponsored studies are accessible at high-volume centers. If clinical trials experience is part of your goal, verify that the program has active endocrine oncology trials with fellow-level involvement, not just faculty-level PI roles.

For programs that describe themselves as primarily clinical, be precise about what "research opportunities" actually means. The ability to write a case series is not the same as protected time and mentorship for funded investigator-initiated research. Ask for the last three fellows' publication records at the program before making a judgment.

Compensation, Funding, and Benefits

Compensation for endocrine oncology advanced fellowship positions is typically benchmarked to the PGY level equivalent for the training year — generally PGY-8 or PGY-9 at most academic centers, depending on prior training duration. For current stipend ranges applicable to your application year, see the PGY Zero compensation data pages and cross-reference your target institution's published GME salary scale or NIH stipend guidelines, where applicable.

Funding mechanisms worth understanding:

• NIH T32 training grants: Some endocrine oncology or cancer biology T32s support fellows at NCI centers. T32 funding comes with research requirements, NIH stipend levels, and eligibility rules around citizenship and visa status. Review the specific T32 award for your program; they are publicly searchable in NIH RePORTER.
• K12 scholar programs: Institutional K12 (career development) awards at NCI-designated centers sometimes support advanced fellows transitioning toward independent investigator status. These are competitive and typically require a research proposal.
• Institutional departmental funding: Many positions are simply funded by the department as a service-weighted clinical fellow, with modest research support. This is neither better nor worse than T32 funding by default — it depends on protected time and mentorship quality.

Standard benefits at academic medical centers for this level of training typically include health and dental insurance, professional liability coverage, conference travel support (variable — ask specifically), and student loan deferment eligibility during training. Confirm loan deferment eligibility with your loan servicer based on your specific loan types; it is not automatic for all post-fellowship positions.

Board Certification and Credentials After Training

There is no ABMS board examination for endocrine oncology. There is no separate certificate you will hold at the end of this training.

Your board certification profile after completing endocrine oncology training will be one or both of the following:

• ABIM certification in endocrinology, diabetes, and metabolism — if you trained in endocrinology as your parent fellowship. This is the primary credential you will hold and present.
• ABIM certification in medical oncology — if you trained in hematology-oncology as your parent fellowship, or if you pursued dual fellowship training (uncommon but not impossible).

Subspecialty expertise in endocrine oncology is documented through your CV, your publication record, your program director's letter, and the institutional appointment verification from the program where you trained. When credentialing at a new employer or hospital system, you will provide documentation of your advanced training as an institutional fellowship completion letter, not an ACGME certificate.

For academic faculty appointment purposes, your record of research output, grant funding, and the reputation of your training program will carry more practical weight than the absence of a separate board certificate. This is a mature norm in the subspecialty and is not a credentialing liability if you trained at a recognized program.

Career Outcomes and Practice Settings

The realistic career pathways for endocrine oncology-trained physicians concentrate in the following settings:

• Academic faculty at NCI-designated comprehensive cancer centers: The most common trajectory for research-track fellows. Entry-level appointments are typically at the instructor or assistant professor level, depending on publication record and grant status at time of hire. Academic endocrine oncology positions at major cancer centers are not abundant — this is a small subspecialty — but they are real and they turn over as senior faculty retire or move to leadership roles.
• Academic endocrinology division with oncology focus: University-based endocrinology divisions at academic medical centers with active cancer programs hire faculty whose primary clinical and research identity is endocrine oncology. This is a broader market than pure cancer center positions.
• NIH intramural program: The NCI intramural program at NIH has endocrine oncology investigators; positions there are highly competitive and require a strong research profile. NIH Lasker Clinical Research Scholars and other mechanisms exist for clinician-scientists in this space.
• Pharmaceutical and biotechnology medical affairs and clinical development: Thyroid cancer (particularly targeted therapy for RET- and BRAF-driven disease), NET therapeutics, and adrenocortical carcinoma are active areas of drug development. Medical affairs and clinical science positions at companies with endocrine oncology pipelines are a realistic industry pathway, typically requiring several years of academic practice first.
• International cancer institutes: High-volume endocrine oncology programs exist in Europe, Canada, Australia, and elsewhere. For US-trained physicians, these are minority pathways but are available.

The honest framing: endocrine oncology is a small subspecialty. The number of dedicated positions — at any level — is limited compared to broader oncology or general endocrinology. Physicians who train in this space and build a research profile around a specific tumor type (thyroid, NETs, adrenal) position themselves more competitively than generalist endocrine oncology trainees. Niche depth, in this field, is a competitive asset.

Program Directory — Endocrine Oncology Fellowships

This directory reflects programs known to offer structured endocrine oncology advanced training based on published institutional information. Accreditation status, duration, and focus areas are noted as described by institutions in public sources. Program availability changes; verify directly with each institution before applying. PGY Zero does not verify case volumes or independently audit program quality claims.

The University of Texas MD Anderson Cancer Center

• Accreditation status: Not a standalone ACGME-accredited program; advanced fellowship under the Department of Endocrine Neoplasia and Hormonal Disorders
• Duration: One to two years
• Focus areas: Thyroid malignancies, NETs, adrenocortical carcinoma, pituitary neoplasms, MEN syndromes, endocrine immunotherapy toxicity, clinical trials
• Notable structure: One of the highest-volume endocrine malignancy programs in the US; multidisciplinary endocrine tumor board, PRRT program, active translational research infrastructure
• Application contact: Department of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center — contact via institutional website

Memorial Sloan Kettering Cancer Center

• Accreditation status: Not a standalone ACGME-accredited program; advanced clinical and research fellowship within endocrinology service
• Duration: One to two years
• Focus areas: Thyroid cancer (including advanced and radioiodine-refractory disease), NETs, endocrine complications of cancer therapy, clinical trials participation
• Notable structure: Integration with MSK's broader medical oncology and nuclear medicine infrastructure; active kinase inhibitor trial portfolio
• Application contact: Endocrinology Service, Memorial Sloan Kettering Cancer Center — contact via institutional website

Mayo Clinic (Rochester)

• Accreditation status: Advanced training within ACGME-accredited endocrinology program or as a post-fellowship institutional appointment; confirm current structure directly
• Duration: One year (typical)
• Focus areas: Thyroid malignancies, NETs, adrenal tumors, hereditary endocrine neoplasia, pituitary tumors
• Notable structure: High case volume across all endocrine tumor types; integrated surgical endocrinology and nuclear medicine; ENETS Center of Excellence designation
• Application contact: Division of Endocrinology, Mayo Clinic Rochester — contact via institutional website

National Institutes of Health — NCI Intramural Program

• Accreditation status: Federal intramural training appointment; not ACGME-accredited; governed by NIH Clinical Center GME and training office frameworks
• Duration: Variable; typically two to three years for clinical research fellows
• Focus areas: Adrenocortical carcinoma, pheochromocytoma/paraganglioma, thyroid cancer genomics, hereditary endocrine tumor syndromes, translational and clinical trial research
• Notable structure: Research-heavy; access to NCI biospecimen repositories, genomics platforms, and NCI cooperative group trials; Lasker Clinical Research Scholar mechanism available for senior candidates
• Application contact: NCI Intramural Research Program — contact through NIH training office and relevant principal investigators; positions posted on NIH Careers

University of Michigan / Michigan Medicine

• Accreditation status: Advanced fellowship within endocrinology division; institutional appointment
• Duration: One to two years
• Focus areas: Thyroid cancer, NETs, adrenal malignancies, endocrine immunotherapy toxicity
• Notable structure: NCI-designated Rogel Cancer Center affiliation; active translational endocrine oncology research program
• Application contact: Division of Metabolism, Endocrinology and Diabetes, Michigan Medicine — contact via institutional website

Other programs with documented endocrine oncology training activity include those at Johns Hopkins, University of Colorado, UC San Francisco, Dana-Farber/Brigham and Women's, and Cleveland Clinic. This list is not exhaustive. Search NCI-designated cancer center endocrinology divisions directly for current availability.

Frequently Asked Questions

Is endocrine oncology ACGME-accredited?

No. As of 2025, there is no ACGME accreditation for endocrine oncology fellowship as a standalone program type. Training occurs under institutional or parent program frameworks. This is accurately described in the accreditation section above and is not expected to change in the near term based on publicly available ACGME subspecialty development information.

Can I do endocrine oncology fellowship after endocrinology fellowship?

Yes. This is the most common pathway. Completion of an ACGME-accredited endocrinology fellowship is the standard prerequisite for most programs. You apply during your endocrinology fellowship, ideally in the second year, for a position starting after you complete training.

Can I do endocrine oncology fellowship after medical oncology fellowship?

Yes, and some programs actively seek oncology-trained fellows for positions with a heavier tumor biology and clinical trials orientation. The clinical emphasis will differ — you will be adding endocrine subspecialty depth rather than oncology framework — and you should evaluate whether a given program's mentorship structure suits that learning direction.

What do endocrine oncologists treat?

The core disease scope is covered in the competencies section above. Briefly: thyroid cancers (all types), adrenocortical carcinoma, pheochromocytoma and paraganglioma, NETs (gastroenteropancreatic, thoracic, and others), parathyroid carcinoma, aggressive pituitary tumors, MEN syndromes, and endocrine toxicities of cancer immunotherapy. In practice, thyroid cancer and NETs generate the majority of clinical volume at most centers.

Is there a match for endocrine oncology fellowships?

No. There is no NRMP match, ERAS application portal, or centralized match process for these positions. Applications go directly to programs, and offers are made by programs independently. This makes proactive networking and early contact more important than in matched pathways.

What is the job market outlook for endocrine oncology?

The subspecialty is small and the number of dedicated positions is limited. Demand for expertise in thyroid cancer management, NET therapeutics, and checkpoint inhibitor endocrinopathies is growing, and that growth is generating new positions — but from a narrow base. Candidates with strong research profiles and a defined tumor-type focus are better positioned than generalists. The field rewards people who build a reputation within it; subspecialty conferences (NANETS, Endocrine Society, ASCO thyroid/NET sessions) are where that reputation is built.

Do I need to be a US citizen or permanent resident to apply?

Citizenship is not a universal requirement, but visa sponsorship availability varies significantly by program and by funding mechanism. T32-funded positions have NIH-defined eligibility rules that include citizenship and residency requirements. Institutionally funded positions depend on the institution's sponsorship capacity and willingness. Verify current requirements directly with ECFMG/Intealth and official sources for your application year, and ask each program explicitly about their sponsorship capacity before investing significant application effort.